Cancer Immunology Immunotherapy, 0340-7004
Journal
1 - 10 out of 13Page size: 10
Publications
- 2020
- E-pub ahead of print
- 2019
- Published
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
Leila Khoja & 24 others, , 1 May 2019, In: Cancer Immunology Immunotherapy. 68, 5, p. 773-785 13 p.Research output: Contribution to journal › Article › peer-review
- 2015
- Published
Developments in cancer vaccines for hepatocellular carcinoma
Yuk Ting Ma & David Adams, 21 Jun 2015, In: Cancer Immunology Immunotherapy. 65, 93.Research output: Contribution to journal › Article › peer-review
- 2014
- Published
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
Lucinda Billingham & Gary Middleton, Feb 2014, In: Cancer Immunology Immunotherapy. 63, 2, p. 175-83 9 p.Research output: Contribution to journal › Article › peer-review
- 2012
- Published
Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?
Gary Middleton, Nicola Annels, 2012, In: Cancer Immunology Immunotherapy. 61, 1, p. 1-7 7 p.Research output: Contribution to journal › Article › peer-review
- 2011
- Published
Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12
Alex Dowell, Steve Lee & Peter Searle, 22 Oct 2011, In: Cancer Immunology Immunotherapy.Research output: Contribution to journal › Article
- Published
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Deborah Stocken, 1 Oct 2011, In: Cancer Immunology Immunotherapy. 60, 10, p. 1419-1430 12 p.Research output: Contribution to journal › Article
- Published
Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma.
Oliver Goodyear, Hayden Pearce, Dickens Pratt & Paul Moss, 23 Jul 2011, In: Cancer Immunology Immunotherapy. 60, p. 1751-1761Research output: Contribution to journal › Article › peer-review
- 2009
- Published
Expression and function of T cell homing molecules in Hodgkin's lymphoma.
Paul Murray, Neil Steven, David Adams & Steve Lee, 1 Jan 2009, In: Cancer Immunology Immunotherapy. 58, 1, p. 85-94 10 p.Research output: Contribution to journal › Article
- 2008
- Published
The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner
Peter Hampson, Dean Kavanagh, Emily Smith, Ke-Qing Wang, Janet Lord & Ed Rainger, 1 Aug 2008, In: Cancer Immunology Immunotherapy. 57, 8, p. 1241-51 11 p.Research output: Contribution to journal › Article